No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XLO Xilio Therapeutics
- 1.090
- +0.080+7.92%
Close Apr 26 16:00 ET
- 1.060
- -0.030-2.75%
Post 17:39 ET
40.23MMarket Cap-392P/E (TTM)
1.110High1.020Low144.16KVolume1.020Open1.010Pre Close154.66KTurnover0.76%Turnover RatioLossP/E (Static)36.91MShares3.30052wk High1.09P/B20.57MFloat Cap0.49052wk Low--Dividend TTM18.88MShs Float27.950Historical High--Div YieldTTM8.91%Amplitude0.490Historical Low1.072Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Xilio Therapeutics Currently May Offer And Sell Shares Of Co's Common Stock Having An Aggregate Offering Price Of Up To $18.7M
Express News | Xilio Therapeutics Inc - Currently May Offer and Sell Shares of Co's Common Stock Having an Aggregate Offering Price of up to $18.7 Mln
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $
Express News | Xilio Therapeutics 13G/Amended Filing Shows Rock Springs Capital Management LP Reported A 8.71% Stake In The Co As Of March 27, 2024
Express News | Xilio Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 19.9% Stake In The Co As Of March 27, 2024
Express News | Xilio Therapeutics Shares Are Trading Lower. The Company Reported Q4 Financial Results
Comments
$Xilio Therapeutics(XLO.US$ why it keep dropping?
1
$Xilio Therapeutics(XLO.US$ Squeeze 😂😂
1
$Xilio Therapeutics(XLO.US$ low high
loading...
1
2
$Xilio Therapeutics(XLO.US$ you guys are really trying to short a cancer treatment drug? You apes
4
$Xilio Therapeutics(XLO.US$ In short term, there is some obstruction from the short. However, in long term it's definitely worth buying. A lot of analysts rating for this stock range from 7-10 dollars. But I'm more confident in Gilead investment.They are definitely not stupid to pay them so much money. It could be acquired by them later.That is why I think.
5
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
健谈的克利夫兰 : 可能是垃圾
。